(Total Views: 310)
Posted On: 07/07/2020 8:08:35 PM
Post# of 36568
New BARDA Award: Novavax Inc. USA
Product Name: NVX-CoV-2373 Vaccine for SARS-CoV-2
Description:
Manufacture and delivery of SARS-CoV-2 vaccine doses, NVX-CoV2373, which is suitable for use in humans under a sufficiently informed deployment strategy, and the advanced positioning of a stockpile of critical long lead raw materials for the Matrix-M adjuvant. The NVX-CoV-2373 vaccine is comprised of the Matrix-M™ adjuvant, and antigen (SARS-CoV-2 spike protein).
Unique Impact:
Successful development of the prototype will demonstrate Novavax’s ability to rapidly stand up and seamlessly transition to large scale manufacturing to meet surge requirements, and demonstrate capability to stockpile and distribute large quantities of the vaccine to respond when needed under EUA or FDA licensure.
Base Award Amount: $1,600,434,523 (July 5, 2020)
Product Name: NVX-CoV-2373 Vaccine for SARS-CoV-2
Description:
Manufacture and delivery of SARS-CoV-2 vaccine doses, NVX-CoV2373, which is suitable for use in humans under a sufficiently informed deployment strategy, and the advanced positioning of a stockpile of critical long lead raw materials for the Matrix-M adjuvant. The NVX-CoV-2373 vaccine is comprised of the Matrix-M™ adjuvant, and antigen (SARS-CoV-2 spike protein).
Unique Impact:
Successful development of the prototype will demonstrate Novavax’s ability to rapidly stand up and seamlessly transition to large scale manufacturing to meet surge requirements, and demonstrate capability to stockpile and distribute large quantities of the vaccine to respond when needed under EUA or FDA licensure.
Base Award Amount: $1,600,434,523 (July 5, 2020)
(0)
(0)
